Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: mike mulhearn who wrote (251)	11/23/1998 12:24:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1073

>> Tumor antigens are proteins produced by tumors but not by normal cells. << Ask Gizzmo to name even one that is expressed on a significant percentage of cancers/lesions. >> our adenoviral vectors containing melanoma tumor antigens MART 1 and gp100 genes were safe and well-tolerated << Not only are these antigens expressed on normal cells (melanocytes), thus negating the definition above, their expression has been shown to be very heterogeneous on cutaneous melanomas. I follow these projects closely, and suggest that you not hold your breath. >> These technologies may allow us to discover novel antigens more quickly and in much greater quantities than previously possible. << Twenty four years and counting, we've heard similar stories. Naive IMO, unless you are talking a patient-specific treatment. That makes for a difficult business plan, and, even then, I suggest that there will be very little benefit to the patient. >> A second and complementary gene immunotherapy approach is the use of stress genes to stimulate an immune response. << This is a viable approach, IMO. I've been suggesting it to the CEO of Cistron Bio for two years, but he's too frigging st**** to recognize a business opportunity. HSPs, inflammatory lymphokines.... no difference, IMO. Would love to be wrong, as I'm a fan of StressGen. >> combines dendritic cells, a type of antigen-presenting cell, with tumor cells << A patient-specific therapy...... wait about 10 years and then invest. I'll comment on your other posts when I have time. Thanks, Mike. Rick